Tomo primero de tratados y sermones de la limpia Concepcion de Nuestra Señora ... : con seys tablas copiosas ...

La 3º y 4 º obra con fecha de 1616Sign.: [ ]2, A8, [calderón]4, A-O8, P6, [calderón]4, A-N8, [calderón]4, A-H8, I6, A10, A-B12, A16, A16, A12, [calderón]-4[calderón]8, 5 [calderón]4Port. con viñeta xil., imagen de la Inmaculada ConcepciónErrores de fol.: en el primero, repite la p. 116 y en el segundo, de h. 94 pasa a la 97Contiene con port. y pag. propia : Dos discursos teologicos en defensa de la Inmaculada Concepcion / Gonçalo Sanchez Luzero . La Virgen Santissima no pecó en Adan / Gonçalo Sanchez Luzero. $tInformacion eclesiastica en defensa de la limpia Concepcion ... / Pedro de Ojeda de la Compañia de Jesus. Sermon que predicó ... Manuel Sarmiento de Mendoça. Sermon del padre Ioan de Pineda. Sermon de la Inmaculada Concepcion / por ... Alonso de Ayala y Guzman. Sermon a la Inmaculada Concepcion ... / por ... Hernando Muñoz. Sermon que predico el licenciado Alonso Gomez de Roxas ... Declamacion que hizo el ... padre Michael AuellánA 096/04

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

Rationale & Objective: It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kid-ney disease varies by age and sex. We assessed the effects of canagliflozin among age group categories and between sexes in the Canagli-flozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study.Study Design: Secondary analysis of a random-ized controlled trial. Setting & Participants: Participants in the CREDENCE trial. Intervention: Participants were randomly assigned to receive canagliflozin 100 mg/d or placebo.Outcomes: Primary composite outcome of kid-ney failure, doubling of serum creatinine con-centration, or death due to kidney or cardiovascular disease. Prespecified secondary and safety outcomes were also analyzed. Out-comes were evaluated by age at baseline (<60, 60-69, and >_70 years) and sex in the intention-to-treat population using Cox regression models.Results: The mean age of the cohort was 63.0 & PLUSMN; 9.2 years, and 34% were female. Older age and female sex were independently associ-ated with a lower risk of the composite of adverse kidney outcomes. There was no evidence that the effect of canagliflozin on the primary outcome (acomposite of kidney failure, a doubling of serum creatinine concentration, or death from kidney or cardiovascular causes) differed between age groups (HRs, 0.67 [95% CI, 0.52-0.87], 0.63 [0.4 8-0.82], and 0.89 [0.61-1.29] for ages <60, 60-69, and >_70 years, respectively; P = 0.3 for interaction) or sexes (HRs, 0.71 [95% CI, 0.5 4-0.95] and 0.69 [0.56-0.8 4] in women and men, respectively; P = 0.8 for interaction). No differences in safety outcomes by age group or sex were observed.Limitations: This was a post hoc analysis with multiple comparisons.Conclusions: Canagliflozin consistently reduced the relative risk of kidney events in people with diabetic kidney disease in both sexes and across age subgroups. As a result of greater background risk, the absolute reduction in adverse kidney outcomes was greater in younger participants.Funding: This post hoc analysis of the CREDENCE trial was not funded. The CREDENCE study was sponsored by Janssen Research and Development and was conducted collaboratively by the sponsor, an academic-led steering committee, and an academic research organization, George Clinical.Trial Registration: The original CREDENCE trial was registered at ClinicalTrials.gov with study number NCT02065791